Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- SEMINAR
December 25, 2006
- Reducing Number of "Cancer Refugees" Would Save \522.7 Billion
December 25, 2006
- Biopharmaceuticals Expected to Show Strongest Growth in Future: JHSF Survey
December 25, 2006
- No Increase in Resistance to Tamiflu Observed: Roche
December 25, 2006
- NEW PRODUCTS
December 25, 2006
- Allergic Rhinitis Affects QOL, Reduces Productivity: Prof. Okamoto
December 25, 2006
- SURVEY 4 articles
December 25, 2006
- Influenza Preventive Effects of Catechin Gargle Reported
December 25, 2006
- SMO Group Holds CRC Training Seminar
December 25, 2006
- AstraZeneca to Simultaneously Start All PI Trials Worldwide
December 25, 2006
- Pazufloxacin Can Now Be Used as 1st-Choice Drug: Toyama, MPC
December 25, 2006
- Sanofi-aventis to Start Large Epidemiological Study in Cerebral Infarction Patients
December 25, 2006
- Chugai to Copromote Otsuka's Antiplatelet Agent Pletaal
December 25, 2006
- Wyeth, Kyushu Univ. Moving Forward with Their R&D Alliance
December 25, 2006
- Pfizer to Continue Launching Series of New Drugs: President Iwasaki
December 25, 2006
- REGULATORY NEWS IN BRIEF
December 25, 2006
- BUSINESS NEWS IN BRIEF
December 25, 2006
- PMDA to Increase Transparency on Posting of Ex-Employees of Companies
December 25, 2006
- Nippon Keidanren Leaders Exchange Opinions with Korosho Leaders
December 25, 2006
- Novartis Highlights Strong R&D Pipeline
December 25, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…